ReCode Therapeutics Investors

30 investors on Angel Roster list ReCode Therapeutics in their portfolio. Most are private equity firms and venture capital firms, the most common stage is Series A and the largest groups are based in the United States, Israel and China.

Investors are matched on the company name in their portfolio, so companies that share the name ReCode Therapeutics can appear together.

Investors listed
30
With verified email
50%
Most common stage
Series A
Top location
United States

Updated October 13, 2026 · How we compile this data

Top 30 ReCode Therapeutics investors

The most complete profiles first. Showing 30 of 30.

  • David BonitaVerified

    Venture Capital, Private Equity Firm, Investor · United States

    SeedSeries AHealth CareInvestment ManagementLife ScienceInformation Technology (IT)

    Portfolio: Edgewise Therapeutics, Syros Pharmaceuticals, Yisheng Biopharma, Evox Therapeutics and 93 more

    Verified email available

  • Geoffrey HsuVerified

    Venture Capital, Private Equity Firm, Investor · United States

    SeedSeries AHealth CareInvestment ManagementLife ScienceInformation Technology (IT)

    Portfolio: Edgewise Therapeutics, Syros Pharmaceuticals, Yisheng Biopharma, Evox Therapeutics and 87 more

    Verified email available

  • Louis BernemanVerified

    Venture Capital, University Program, Entrepreneurship Program · United States

    Series AHealth CareGeneticsPaymentsCybersecurity

    Portfolio: CounterFlow, Infinite Uptime, Modis Therapeutics, Vor Biopharma and 64 more

    Verified email available

  • Manny StockmanVerified

    Venture Capital, University Program, Entrepreneurship Program · United States

    Series AHealth CareGeneticsPaymentsCybersecurity

    Portfolio: CounterFlow, Infinite Uptime, Modis Therapeutics, Vor Biopharma and 64 more

    Verified email available

  • Robert AdelsonVerified

    Venture Capital, University Program, Investor · United States

    Series AHealth CareGeneticsPaymentsCybersecurity

    Portfolio: CounterFlow, Infinite Uptime, Modis Therapeutics, Vor Biopharma and 65 more

    Verified email available

  • Anurag AgarwalVerified

    Venture Capital, University Program, Entrepreneurship Program · United States

    Health CareGeneticsPaymentsCybersecurity

    Portfolio: CounterFlow, Infinite Uptime, Modis Therapeutics, Vor Biopharma and 64 more

    Verified email available

  • Brian GoodmanVerified

    Venture Capital, Private Equity Firm, Investment Partner · United States

    Health CareGeneticsLife ScienceInformation Technology (IT)

    Portfolio: CoStim Pharmaceuticals, InformedDNA, Mitobridge, Verastem Oncology and 56 more

    Verified email available

  • Jonathan SilversteinVerified

    Private Equity Firm · United States

    Health CareLife ScienceInformation Technology (IT)Mobile

    Portfolio: Edgewise Therapeutics, Syros Pharmaceuticals, Yisheng Biopharma, Evox Therapeutics and 87 more

    Verified email available

  • Jonathan WangVerified

    Private Equity Firm · China

    Health CareLife ScienceInformation Technology (IT)Mobile

    Portfolio: Edgewise Therapeutics, Syros Pharmaceuticals, Yisheng Biopharma, Evox Therapeutics and 87 more

    Verified email available

  • Luke EvninVerified

    Venture Capital, Private Equity Firm · United States

    Health CareGeneticsLife ScienceInformation Technology (IT)

    Portfolio: CoStim Pharmaceuticals, InformedDNA, Mitobridge, Verastem Oncology and 56 more

    Verified email available

  • Matt CohenVerified

    Venture Capital, University Program · United States

    Health CareGeneticsPaymentsCybersecurity

    Portfolio: CounterFlow, Infinite Uptime, Modis Therapeutics, Vor Biopharma and 64 more

    Verified email available

  • Rishi GuptaVerified

    Private Equity Firm · United States

    Health CareInvestment ManagementLife ScienceInformation Technology (IT)

    Portfolio: Edgewise Therapeutics, Syros Pharmaceuticals, Yisheng Biopharma, Evox Therapeutics and 87 more

    Verified email available

  • Shinichiro FuseVerified

    Venture Capital, Private Equity Firm · United States

    Health CareGeneticsLife ScienceInformation Technology (IT)

    Portfolio: CoStim Pharmaceuticals, InformedDNA, Mitobridge, Verastem Oncology and 56 more

    Verified email available

  • Todd FoleyVerified

    Venture Capital, Private Equity Firm, Investment Partner · United States

    Health CareGeneticsLife ScienceInformation Technology (IT)

    Portfolio: CoStim Pharmaceuticals, InformedDNA, Mitobridge, Verastem Oncology and 56 more

    Verified email available

  • Carter Neild

    Venture Capital, Private Equity Firm, Investor · United States

    SeedSeries AHealth CareInvestment ManagementLife ScienceInformation Technology (IT)

    Portfolio: Edgewise Therapeutics, Syros Pharmaceuticals, Yisheng Biopharma, Evox Therapeutics and 87 more

    Contact details available

  • Chau Khuong

    Venture Capital, Private Equity Firm, Investor · United States

    SeedSeries AHealth CareLife ScienceInformation Technology (IT)Mobile

    Portfolio: Edgewise Therapeutics, Syros Pharmaceuticals, Gennao Bio, Yisheng Biopharma and 89 more

    Contact details available

  • Ed Hurwitz

    Venture Capital, Private Equity Firm, Investor · United States

    SeedHealth CareGeneticsLife ScienceInformation Technology (IT)

    Portfolio: CoStim Pharmaceuticals, Protego Biopharma, InformedDNA, Mitobridge and 60 more

    Contact details available

  • Marc Singer

    Venture Capital, University Program, Entrepreneurship Program · United States

    Series AHealth CareGeneticsPaymentsCybersecurity

    Portfolio: CounterFlow, Infinite Uptime, Modis Therapeutics, Vor Biopharma and 69 more

    Contact details available

  • Scotland Stevens

    Venture Capital, Private Equity Firm, Investor · United States

    SeedSeries AHealth CareInvestment ManagementLife ScienceInformation Technology (IT)

    Portfolio: Edgewise Therapeutics, Syros Pharmaceuticals, Yisheng Biopharma, Evox Therapeutics and 87 more

    Contact details available

  • Stephen Curtis

    Venture Capital, Private Equity Firm, Investor · United States

    SeedHealth CareGeneticsLife ScienceInformation Technology (IT)

    Portfolio: CoStim Pharmaceuticals, InformedDNA, Mitobridge, Verastem Oncology and 56 more

    Contact details available

  • William Harrington

    Venture Capital, University Program, Investor · United States

    Series AHealth CareGeneticsPaymentsCybersecurity

    Portfolio: CounterFlow, Infinite Uptime, Modis Therapeutics, Vor Biopharma and 71 more

    Contact details available

  • Anat Naschitz

    Private Equity Firm · Israel

    Health CareLife ScienceInformation Technology (IT)Mobile

    Portfolio: Edgewise Therapeutics, Syros Pharmaceuticals, Yisheng Biopharma, Evox Therapeutics and 87 more

    Contact details available

  • Christiana Bardon M.D.

    Venture Capital, Private Equity Firm, Investment Partner · United States

    Health CareGeneticsInvestment ManagementLife Science

    Portfolio: CoStim Pharmaceuticals, InformedDNA, Mitobridge, Verastem Oncology and 56 more

    Contact details available

  • Erez Chimovits

    Private Equity Firm · Israel

    Health CareInvestment ManagementLife ScienceInformation Technology (IT)

    Portfolio: Edgewise Therapeutics, Syros Pharmaceuticals, Yisheng Biopharma, Evox Therapeutics and 87 more

    Contact details available

  • Kirsten Leute

    Venture Capital, University Program · United States

    Health CareGeneticsPaymentsCybersecurity

    Portfolio: CounterFlow, Infinite Uptime, Modis Therapeutics, Vor Biopharma and 64 more

    Contact details available

  • Leigh Zawel

    Venture Capital, Private Equity Firm · United States

    Health CareGeneticsLife ScienceInformation Technology (IT)

    Portfolio: CoStim Pharmaceuticals, InformedDNA, Mitobridge, Verastem Oncology and 56 more

    Contact details available

  • Vinay Bhaskar

    Venture Capital, Private Equity Firm · United States

    Health CareGeneticsLife ScienceInformation Technology (IT)

    Portfolio: CoStim Pharmaceuticals, InformedDNA, Mitobridge, Verastem Oncology and 56 more

    Contact details available

  • Sundeep AgrawalVerified

    Private Equity Firm · United States

    Health CareWellnessWomen FoundedLife Science

    Portfolio: Ignyta, Silverback Therapeutics, Erasca, ReCode Therapeutics and 1 more

    Verified email available

  • Darren Blanton

    Private Equity Firm · United States

    Health CareWellnessWomen FoundedLife Science

    Portfolio: Ignyta, Silverback Therapeutics, Erasca, ReCode Therapeutics and 1 more

    Contact details available

  • Helen S. Kim

    Venture Capital, Angel/Individual, Investor · United States

    SeedPre-SeedBiotechnologyPharmaceuticals

    Portfolio: ReCode Therapeutics, IconOVir Bio, PACT Pharma

    Contact details available

Frequently asked questions

How many ReCode Therapeutics investors are on Angel Roster?

Angel Roster lists 30 ReCode Therapeutics investors. 15 of them (50%) include a verified email address.

What types of investors are they?

The most common investor types are Private Equity Firms (25), Venture Capital Firms (23) and University Program Investors (8). An investor can have more than one type, for example an angel who is also a venture partner.

Which stages do ReCode Therapeutics investors invest in?

Among those that list a stage, the most common are Series A (10), Seed (8) and Pre-Seed (1).

Where are ReCode Therapeutics investors based?

Most are based in the United States (27), Israel (2) and China (1).

Which companies have ReCode Therapeutics investors backed?

The most-backed portfolio companies among them are Cullinan Oncology (19), Repare Therapeutics (19), Q32 Bio (18), ESCAPE Bio (18) and Cleave Therapeutics (18).

How do I contact ReCode Therapeutics investors?

Create a free Angel Roster account to search and filter all 30, then unlock verified emails and LinkedIn profiles on a paid plan. Every plan starts with a 3-day free trial.